PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24468788-8	2014	Lapatinib, CI-1033, erlotinib, axitinib, sunitinib, PKI-166, and AEE788 inhibited the replication of bloodstream T. brucei, with a 50% growth inhibitory concentration (GI50) between 1.3 muM and 2.5 muM.	Lapatinib	0-9	latexin	Homo sapiens	186-189	
29902719-5	2018	Additionally, 27b efficiently thwarted the proliferation of lapatinib-resistant human non-small lung carcinoma (NCI-H1975) cells, harboring T790 M mutation, with IC50 of 4.2 muM.	Lapatinib	60-69	latexin	Homo sapiens	174-177	
26238995-6	2015	RESULTS: Following 12 ours treatment with different HER2-inhibitors in the BT474 cell-line; compared to the untreated cells, 16 proteins changed significantly in abundance following lapatinib treatment (1 muM), 21 proteins changed significantly following neratinib treatment (150 nM) and 38 proteins changed significantly following afatinib treatment (150 nM).	Lapatinib	182-191	latexin	Homo sapiens	205-208	
24468788-8	2014	Lapatinib, CI-1033, erlotinib, axitinib, sunitinib, PKI-166, and AEE788 inhibited the replication of bloodstream T. brucei, with a 50% growth inhibitory concentration (GI50) between 1.3 muM and 2.5 muM.	Lapatinib	0-9	latexin	Homo sapiens	198-201	
24191259-9	2014	Furthermore, pretreatment with 25 muM l-buthionine sulfoximine to deplete intracellular glutathione markedly enhanced lapatinib cytotoxicity.	Lapatinib	118-127	latexin	Homo sapiens	34-37	
23375200-10	2013	Lapatinib (10 muM) inhibited FSH/LH-induced oocyte meiotic maturation.	Lapatinib	0-9	latexin	Homo sapiens	14-17	
23375200-11	2013	Progesterone production increased after OCC stimulation with FSH/LH and was significantly decreased by lapatinib (10 muM).	Lapatinib	103-112	latexin	Homo sapiens	117-120	
22370628-8	2012	At 5 muM lapatinib, the introduction of dexamethasone 20 muM produced a 59% decline in viability.	Lapatinib	9-18	latexin	Homo sapiens	57-60